Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2735788 | 0.92 | MAOB (0.76) | MAOBMEN1KMT2ACYP1A2LMNA | |
| SCHEMBL1834526 | 0.86 | CYP1A2 (0.67) | MAOBMEN1KMT2ACYP1A2LMNA | |
| SCHEMBL18002534 | 0.84 | MAOB (0.65) | MAOBMEN1KMT2ACYP1A2LMNA | |
| SCHEMBL4971327 | 0.83 | MAOB (0.63) | MAOBMEN1KMT2ACYP1A2LMNA | |
| SCHEMBL22489859 | 0.83 | MAOB (0.63) | MAOBMEN1KMT2ACYP1A2LMNA | |
| SCHEMBL2007390 | 0.82 | CYP1A2 (0.67) | MAOBMEN1KMT2ACYP1A2LMNA | |
| SCHEMBL9841807 | 0.80 | MAOB (0.69) | MAOBMEN1KMT2ACYP1A2LMNA | |
| SCHEMBL538272 | 0.80 | MAOB (0.69) | MAOBFFAR1FFAR4NR4A2MAOA | |
| SCHEMBL30344886 | 0.80 | MAOB (0.69) | MAOBFFAR1FFAR4NR4A2MAOA | |
| SCHEMBL2655613 | 0.80 | MAOB (0.55) | MAOBMEN1KMT2ACYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486992-B2 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED (GB) | 2013-07-16 | — | — | US | disclosed |
| US-8268881-B2 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED (GB) | 2012-09-18 | — | — | US | disclosed |
| CN-101268046-B | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER | 2012-07-25 | — | — | CN | disclosed |
| US-8227506-B2 | Benzamidine compound | AJINOMOTO., INC. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-8088768-B2 | Protein kinase and phosphatase inhibitors | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088768-B2 | Protein kinase and phosphatase inhibitors | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088768-B2 | Protein kinase and phosphatase inhibitors | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110251164-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2011-10-13 | — | — | US | disclosed |
| US-20110136807-A1 | Bicyclic compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136807-A1 | Bicyclic compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20070105831-A1 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED | 2007-05-10 | — | — | US | disclosed |
| WO-2007034325-A1 | CARBOXAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2007-03-29 | — | — | WO | disclosed |
| US-7129225-B2 | Protection against and treatment of hearing loss | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060172971-A1 | Protection against and treatment of hearing loss | NICOTERA THOMAS | 2006-08-03 | — | — | US | disclosed |
| US-7005445-B2 | Protein kinase and phosphatase inhibitors and methods for designing them | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-02-28 | — | — | US | disclosed |
| US-20060030544-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2006-02-09 | — | — | US | disclosed |
| EP-1444204-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS, METHODS FOR DESIGNING THEM, AND METHODS OF USING THEM | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040019015-A1 | Protection against and treatment of hearing loss | HEALTH RESEARCH, INC. (ROSWELL PARK DIVISION) | 2004-01-29 | — | — | US | disclosed |
| US-20030166615-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2003-09-04 | — | — | US | disclosed |
| WO-2003035621-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS, METHODS FOR DESIGNING THEM, AND METHODS OF USING THEM | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251164-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | MAOB 283/4885MEN1 2293/4885KMT2A 1658/4885 |
| US-20060030544-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | PTPN5, PTPN2, PTPN6 | MAOB 3237/4885MEN1 3990/4885KMT2A 2269/4885 |
| US-20060172971-A1 | Protection against and treatment of hearing loss | NTRK2, AIFM2, AIFM1 | MAOB 514/4885MEN1 1804/4885KMT2A 2446/4885 |
| US-20070105831-A1 | Carboxamide derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | MAOB 283/4885MEN1 2293/4885KMT2A 1658/4885 |
| US-20040019015-A1 | Protection against and treatment of hearing loss | NTRK2, AIFM2, AIFM1 | MAOB 514/4885MEN1 1804/4885KMT2A 2446/4885 |
| US-20110136807-A1 | Bicyclic compositions and methods for modulating a kinase cascade | MAP3K20, MAP3K6, MAP3K2 | MAOB 2718/4885MEN1 2882/4885KMT2A 2247/4885 |
| US-20030166615-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | PTPN5, PTPN2, PTPN6 | MAOB 3237/4885MEN1 3990/4885KMT2A 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.